Late of Sunday, Emergent BioSolutions Inc said, a key U.S. agency has increased an order related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.
“The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility,” said the company in a statement while adding, ramping up manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance, is also on the cards.
Categories: Creativity, Entrepreneurship, HR & Organization, Strategy
Leave a Reply